AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Apnimed to Present at the 20th Annual Needham Virtual Healthcare Conference

April 12, 2021 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2021--

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the 20 th Annual Needham Virtual Healthcare Conference, held April 12-15, 2021. Apnimed’s presentation is scheduled for Thursday, April 15 th at 3:45 pm ET.

Webcast Link:

A live webcast of Apnimed’s session will be available in the Events section of the Company’s website at https://apnimed.com/events/ or can be accessed via the following link: https://wsw.com/webcast/needham107/apni/2238544

ADVERTISEMENT

A replay of the presentation will be archived on Apnimed’s website.

About Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and affects approximately six percent of women and 13 percent of men in the U.S., totaling more than 25 million Americans. OSA is characterized by partial or complete upper airway occlusion that occurs during sleep which may lead to poor sleep, and in the long-term, hypertension, diabetes, cardiovascular disease, strokes, and early mortality. OSA is also a major cause of motor vehicle accidents and workplace injuries. Over 80 percent of diagnosed patients are prescribed positive pressure devices such as CPAP, but only 30-40 percent are compliant long-term, leaving a significant population untreated and at risk. Apnimed expects its pharmacologic therapies to transform treatment of this serious sleep disorder.

About AD109

Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep. AD109 is a first-in-class, oral pharmaceutical combination dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI) with a low dose of our novel NCE selective antimuscarinic. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments.

ADVERTISEMENT

About Apnimed

Apnimed is a clinical-stage company working to transform the treatment of sleep apnea based on a simple idea – patients will benefit from safe and effective oral drug treatment. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. To learn more visit Apnimed.com or follow the company on LinkedIn and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210412005521/en/

CONTACT: Media Contact:

Courtney Heath

ScientPR

courtney@scientpr.com

617-872-2462Investor Contact:

Elizabeth Woo

Kendall IR

ewoo@kendallir.com

617-733-2165

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY

SOURCE: Apnimed

Copyright Business Wire 2021.

PUB: 04/12/2021 10:00 AM/DISC: 04/12/2021 10:01 AM

http://www.businesswire.com/news/home/20210412005521/en